Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by grosdavidon May 01, 2020 9:34am
80 Views
Post# 30975394

I honestly am not worried with today’s

I honestly am not worried with today’s

trading, if ever it trades under 0,45$, I'll see this as an opportunity to buy more shares knowing that there is no risk this company is valued lower than 0,40$.

I also think, in another mentality, that the cost of holding this company has an advantage, because there is a good chance that this company may be part of the solution for COVID19. 

 

Some say the stock will drop to 0,40$, but the thing is : can anyone take part of the PP at 0,40$ honestly? I think the answer is no, because usually privileged investors can ifn't it will be small institutions no? If market trades back to 0,40$, in my head this will not be correct because it is not true that I could get some shares from that PP. I' bringing back economical studies from University relating that the demand and offer. If this trades at 0,40$, this should mean that I would be more advantaged to buy shares from the PP, but I can't, there is an opportunity cost related to that that the market, being not efficient, will allow. That is when retail investors can take advantage. 


I think if you see this as a proof that the company is "valued" at 0,40$, this isn't what it means and it isn't the case.

See the globality of AGN, with the recent updates and NR, you guys know where this is going. Don't doubt it, hold.

David

 

Bullboard Posts